Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weaver, A
Right arrow Articles by Testa, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weaver, A
Right arrow Articles by Testa, N.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Increased numbers of long-term culture-initiating cells in the apheresis product of patients randomized to receive increasing doses of stem cell factor administered in combination with chemotherapy and a standard dose of granulocyte colony-stimulating factor

A Weaver, D Ryder, D Crowther, TM Dexter and NG Testa

Cancer Research Campaign Department of Experimental Haematology, Christie Hospital, Manchester, UK.

Long-term culture-initiating cells (LTC-IC) are arguably the most primitive human hematopoietic cells detectable by in vitro functional assays. We have investigated the mobilization of these cells into the blood of patients with ovarian carcinoma randomized to receive granulocyte colony-stimulating factor (G-CSF; 5 micrograms/kg) plus different doses of stem cell factor (SCF; c-kit ligand) after chemotherapy or G-CSF alone after chemotherapy. We have shown a significant SCF dose response for the mobilization of LTC-IC, with a 5.8-fold increase in LTC-IC mobilization in those patients receiving chemotherapy, G-CSF, and 20 micrograms/kg of SCF, the highest dose used, compared with the patients receiving chemotherapy and G-CSF alone. We have shown a threefold increase in CD34+ cells and up to a 64- fold increase in CD34+/33- cells was seen in patients treated with chemotherapy, G-CSF, and 20 micrograms/kg of SCF compared with those patients treated with chemotherapy and G-CSF alone. However, significant numbers of CD34+/38- cells were only found in the patients receiving 20 micrograms/kg of SCF as part of their mobilization regimen. Patients receiving chemotherapy plus G-CSF and SCF have enhanced mobilization of primitive cells and of the more committed progenitor cells compared with those patients receiving chemotherapy followed by G-CSF alone.

Volume 88, Issue 9, pp. 3323-3328, 11/01/1996
Copyright © 1996 by The American Society of Hematology


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
A. Zeuner, F. Pedini, M. Signore, U. Testa, E. Pelosi, C. Peschle, and R. De Maria
Stem cell factor protects erythroid precursor cells from chemotherapeutic agents via up-regulation of BCL-2 family proteins
Blood, July 1, 2003; 102(1): 87 - 93.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
P. Hematti, S. E. Sellers, B. A. Agricola, M. E. Metzger, R. E. Donahue, and C. E. Dunbar
Retroviral transduction efficiency of G-CSF+SCF-mobilized peripheral blood CD34+ cells is superior to G-CSF or G-CSF+Flt3-L-mobilized cells in nonhuman primates
Blood, March 15, 2003; 101(6): 2199 - 2205.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
S. Siena, R. Schiavo, P. Pedrazzoli, and C. Carlo-Stella
Therapeutic Relevance of CD34 Cell Dose in Blood Cell Transplantation for Cancer Therapy
J. Clin. Oncol., March 13, 2000; 18(6): 1360 - 1377.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
T. Facon, J.-L. Harousseau, F. Maloisel, M. Attal, J. Odriozola, A. Alegre, W. Schroyens, C. Hulin, R. Schots, P. Marin, et al.
Stem Cell Factor in Combination With Filgrastim After Chemotherapy Improves Peripheral Blood Progenitor Cell Yield and Reduces Apheresis Requirements in Multiple Myeloma Patients: A Randomized, Controlled Trial
Blood, August 15, 1999; 94(4): 1218 - 1225.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
W. A. Franklin, J. Glaspy, S. M. Pflaumer, R. B. Jones, L. Hami, C. Martinez, J. R. Murphy, and E. J. Shpall
Incidence of Tumor-Cell Contamination in Leukapheresis Products of Breast Cancer Patients Mobilized With Stem Cell Factor and Granulocyte Colony-Stimulating Factor (G-CSF) or With G-CSF Alone
Blood, July 1, 1999; 94(1): 340 - 347.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
U. Erben, E. Thiel, and M. Notter
Differential Effects of a Stem Cell Factor-Immunoglobulin Fusion Protein on Malignant and Normal Hematopoietic Cells
Cancer Res., June 1, 1999; 59(12): 2924 - 2930.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. J. Shpall, C. A. Wheeler, S. A. Turner, S. Yanovich, R. A. Brown, A. L. Pecora, T. C. Shea, K. F. Mangan, S. F. Williams, C. F. LeMaistre, et al.
A Randomized Phase 3 Study of Peripheral Blood Progenitor Cell Mobilization With Stem Cell Factor and Filgrastim in High-Risk Breast Cancer Patients
Blood, April 15, 1999; 93(8): 2491 - 2501.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. H. Nocka, B. A. Levine, J.-L. Ko, P. M. Burch, B. E. Landgraf, R. Segal, and R. Lobell
Increased Growth Promoting But Not Mast Cell Degranulation Potential of a Covalent Dimer of c-Kit Ligand
Blood, November 15, 1997; 90(10): 3874 - 3883.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
C.G. Begley, R. Basser, R. Mansfield, B. Thomson, W.R.L. Parker, J. Layton, B. To, J. Cebon, W.P. Sheridan, R.M. Fox, et al.
Enhanced Levels and Enhanced Clonogenic Capacity of Blood Progenitor Cells Following Administration of Stem Cell Factor Plus Granulocyte Colony-Stimulating Factor to Humans
Blood, November 1, 1997; 90(9): 3378 - 3389.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J.A. Glaspy, E.J. Shpall, C.F. LeMaistre, R.A. Briddell, D.M. Menchaca, S.A. Turner, M. Lill, L. Chap, R. Jones, M.D. Wiers, et al.
Peripheral Blood Progenitor Cell Mobilization Using Stem Cell Factor in Combination With Filgrastim in Breast Cancer Patients
Blood, October 15, 1997; 90(8): 2939 - 2951.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
K. P. Schofield, G. Rushton, M. J. Humphries, T. M. Dexter, and J. T. Gallagher
Influence of Interleukin-3 and Other Growth Factors on alpha 4beta 1 Integrin-Mediated Adhesion and Migration of Human Hematopoietic Progenitor Cells
Blood, September 1, 1997; 90(5): 1858 - 1866.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
V. C. Broudy
Stem Cell Factor and Hematopoiesis
Blood, August 15, 1997; 90(4): 1345 - 1364.
[Full Text] [PDF]


Home page
BloodHome page
T. Papayannopoulou, B. Nakamoto, R. G. Andrews, S. D. Lyman, and M. Y. Lee
In Vivo Effects of Flt3/Flk2 Ligand on Mobilization of Hematopoietic Progenitors in Primates and Potent Synergistic Enhancement With Granulocyte Colony-Stimulating Factor
Blood, July 15, 1997; 90(2): 620 - 629.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 1996 by American Society of Hematology         Online ISSN: 1528-0020